{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:42:49Z","timestamp":1769859769355,"version":"3.49.0"},"publisher-location":"New York, NY","reference-count":40,"publisher":"Springer New York","isbn-type":[{"value":"9781493986507","type":"print"},{"value":"9781493986514","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-8651-4_3","type":"book-chapter","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T12:51:17Z","timestamp":1535719877000},"page":"57-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy"],"prefix":"10.1007","author":[{"given":"Hae-Won","family":"Son","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,1]]},"reference":[{"issue":"8","key":"3_CR1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"SJ Kolb","year":"2011","unstructured":"Kolb SJ, Kissel JT (2011) Spinal muscular atrophy: a timely review. Arch Neurol 68(8):979\u2013984. \nhttps:\/\/doi.org\/10.1001\/archneurol.2011.74","journal-title":"Arch Neurol"},{"issue":"9630","key":"3_CR2","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH (2008) Spinal muscular atrophy. Lancet 371(9630):2120\u20132133. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(08)60921-6","journal-title":"Lancet"},{"issue":"October","key":"3_CR3","first-page":"499","volume":"5","author":"M Oskoui","year":"1993","unstructured":"Oskoui M, Kaufmann P (1993) Spinal muscular atrophy. Neurotherapeutics 5(October):499\u2013506","journal-title":"Neurotherapeutics"},{"key":"3_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcdb.2014.04.026","volume":"32","author":"DK Li","year":"2014","unstructured":"Li DK, Tisdale S, Lotti F et al (2014) SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Semin Cell Dev Biol 32:22\u201329. \nhttps:\/\/doi.org\/10.1016\/j.semcdb.2014.04.026","journal-title":"Semin Cell Dev Biol"},{"issue":"2","key":"3_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/104303403321070874","volume":"14","author":"CJ DiDonato","year":"2003","unstructured":"DiDonato CJ, Parks RJ, Kothary R (2003) Development of a gene therapy strategy for the restoration of survival motor neuron protein expression: implications for spinal muscular atrophy therapy. Hum Gene Ther 14(2):179\u2013188. \nhttps:\/\/doi.org\/10.1089\/104303403321070874","journal-title":"Hum Gene Ther"},{"issue":"22","key":"3_CR6","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1093\/hmg\/ddv329","volume":"24","author":"H Zhou","year":"2015","unstructured":"Zhou H, Meng J, Marrosu E et al (2015) Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Hum Mol Genet 24(22):6265\u20136277. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddv329","journal-title":"Hum Mol Genet"},{"issue":"1","key":"3_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.12813","volume":"1366","author":"MH Wertz","year":"2016","unstructured":"Wertz MH, Sahin M (2016) Developing therapies for spinal muscular atrophy. Ann N Y Acad Sci 1366(1):5\u201319. \nhttps:\/\/doi.org\/10.1111\/nyas.12813","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"3_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ et al (2006) Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26(4):1333\u20131346. \nhttps:\/\/doi.org\/10.1128\/MCB.26.4.1333-1346.2006","journal-title":"Mol Cell Biol"},{"issue":"3","key":"3_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4161\/rna.6.3.8723","volume":"6","author":"NN Singh","year":"2009","unstructured":"Singh NN, Shishimorova M, Cao LC et al (2009) A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol 6(3):341\u2013350","journal-title":"RNA Biol"},{"issue":"9","key":"3_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/gt.2017.34","volume":"24","author":"NN Singh","year":"2017","unstructured":"Singh NN, Howell MD, Androphy EJ et al (2017) How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther 24(9):520\u2013526. \nhttps:\/\/doi.org\/10.1038\/gt.2017.34","journal-title":"Gene Ther"},{"issue":"2","key":"3_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2017.0665","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A (2017) FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther 27(2):67\u201369. \nhttps:\/\/doi.org\/10.1089\/nat.2017.0665","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"3_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","volume":"24","author":"HM Hsieh-Li","year":"2000","unstructured":"Hsieh-Li HM, Chang JG, Jong YJ et al (2000) A mouse model for spinal muscular atrophy. Nat Genet 24(1):66\u201370. \nhttps:\/\/doi.org\/10.1038\/71709","journal-title":"Nat Genet"},{"issue":"18","key":"3_CR13","doi-asserted-by":"publisher","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","volume":"94","author":"B Schrank","year":"1997","unstructured":"Schrank B, Gotz R, Gunnersen JM et al (1997) Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A 94(18):9920\u20139925. \nhttps:\/\/doi.org\/10.1073\/pnas.94.18.9920","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"3_CR14","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G et al (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24(15):1634\u20131644. \nhttps:\/\/doi.org\/10.1101\/gad.1941310","journal-title":"Genes Dev"},{"issue":"15","key":"3_CR15","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1101\/gad.1961710","volume":"24","author":"AH Burghes","year":"2010","unstructured":"Burghes AH, McGovern VL (2010) Antisense oligonucleotides and spinal muscular atrophy: skipping along. Genes Dev 24(15):1574\u20131579. \nhttps:\/\/doi.org\/10.1101\/gad.1961710","journal-title":"Genes Dev"},{"issue":"6","key":"3_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14712598.2014.896335","volume":"14","author":"A Touznik","year":"2014","unstructured":"Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14(6):809\u2013819. \nhttps:\/\/doi.org\/10.1517\/14712598.2014.896335","journal-title":"Expert Opin Biol Ther"},{"issue":"72","key":"3_CR17","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini MA, Bu J, Richards AM et al (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3(72):72ra18. \nhttps:\/\/doi.org\/10.1126\/scitranslmed.3001777","journal-title":"Sci Transl Med"},{"issue":"May","key":"3_CR18","doi-asserted-by":"publisher","first-page":"11746","DOI":"10.1038\/srep11746","volume":"5","author":"M Nizzardo","year":"2015","unstructured":"Nizzardo M, Simone C, Dametti S et al (2015) Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches. Sci Rep 5(May):11746. \nhttps:\/\/doi.org\/10.1038\/srep11746","journal-title":"Sci Rep"},{"issue":"3","key":"3_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJ Lee","year":"2013","unstructured":"Lee JJ, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3(3):144\u2013176. \nhttps:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"J Pers Med"},{"issue":"4","key":"3_CR20","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.3390\/molecules22040563","volume":"22","author":"V Sardone","year":"2017","unstructured":"Sardone V, Zhou H, Muntoni F et al (2017) Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules 22(4):E563. \nhttps:\/\/doi.org\/10.3390\/molecules22040563","journal-title":"Molecules"},{"issue":"7","key":"3_CR21","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","volume":"21","author":"PN Porensky","year":"2012","unstructured":"Porensky PN, Mitrpant C, McGovern VL et al (2012) A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 21(7):1625\u20131638. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddr600","journal-title":"Hum Mol Genet"},{"issue":"3","key":"3_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/hum.2012.211","volume":"24","author":"H Zhou","year":"2013","unstructured":"Zhou H, Janghra N, Mitrpant C et al (2013) A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther 24(3):331\u2013342. \nhttps:\/\/doi.org\/10.1089\/hum.2012.211","journal-title":"Hum Gene Ther"},{"issue":"12","key":"3_CR23","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shimo","year":"2014","unstructured":"Shimo T, Tachibana K, Saito K et al (2014) Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res 42(12):8174\u20138187. \nhttps:\/\/doi.org\/10.1093\/nar\/gku512","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1074-5521(00)00058-2","volume":"8","author":"DA Braasch","year":"2001","unstructured":"Braasch DA, Corey DR (2001) Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol 8(1):1\u20137","journal-title":"Chem Biol"},{"issue":"1","key":"3_CR25","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1038\/s41598-017-03850-2","volume":"7","author":"A Touznik","year":"2017","unstructured":"Touznik A, Maruyama R, Hosoki K et al (2017) LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Sci Rep 7(1):3672. \nhttps:\/\/doi.org\/10.1038\/s41598-017-03850-2","journal-title":"Sci Rep"},{"key":"3_CR26","doi-asserted-by":"crossref","unstructured":"Maruyama R, Touznik A, Yokota T (2018) Evaluation of exon inclusion induced by splice switching antisense oligonucleotides in SMA patients fibroblasts. J Vis Exp (135).\u00a0\nhttps:\/\/doi.org\/10.3791\/57530","DOI":"10.3791\/57530"},{"issue":"7","key":"3_CR27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"31","author":"M Hache","year":"2016","unstructured":"Hache M, Swoboda KJ, Sethna N et al (2016) Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol 31(7):899\u2013906. \nhttps:\/\/doi.org\/10.1177\/0883073815627882","journal-title":"J Child Neurol"},{"issue":"16","key":"3_CR28","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 114(16):4213\u20134218. \nhttps:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1101\/gad.256644.114","volume":"29","author":"Y Hua","year":"2015","unstructured":"Hua Y, Liu YH, Sahashi K et al (2015) Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev 29(3):288\u2013297. \nhttps:\/\/doi.org\/10.1101\/gad.256644.114","journal-title":"Genes Dev"},{"issue":"7367","key":"3_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F et al (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478(7367):123\u2013126. \nhttps:\/\/doi.org\/10.1038\/nature10485","journal-title":"Nature"},{"issue":"39","key":"3_CR31","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond SM, Hazell G, Shabanpoor F et al (2016) Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A 113(39):10962\u201310967. \nhttps:\/\/doi.org\/10.1073\/pnas.1605731113","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"3_CR32","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1093\/hmg\/ddi205","volume":"14","author":"J Jarecki","year":"2005","unstructured":"Jarecki J, Chen X, Bernardino A et al (2005) Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 14(14):2003\u20132018. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddi205","journal-title":"Hum Mol Genet"},{"issue":"24","key":"3_CR33","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/hmg\/10.24.2841","volume":"10","author":"C Andreassi","year":"2001","unstructured":"Andreassi C, Jarecki J, Zhou J et\u00a0al (2001) Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 10(24):2841\u20132849. \nhttps:\/\/doi.org\/10.1093\/hmg\/10.24.2841","journal-title":"Hum Mol Genet"},{"issue":"17","key":"3_CR34","doi-asserted-by":"publisher","first-page":"9808","DOI":"10.1073\/pnas.171105098","volume":"98","author":"JG Chang","year":"2001","unstructured":"Chang JG, Hsieh-Li HM, Jong YJ et al (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 98(17):9808\u20139813. \nhttps:\/\/doi.org\/10.1073\/pnas.171105098","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","volume":"8","author":"EW Ottesen","year":"2017","unstructured":"Ottesen EW (2017) ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci 8(1):1\u20136. \nhttps:\/\/doi.org\/10.1515\/tnsci-2017-0001","journal-title":"Transl Neurosci"},{"issue":"4","key":"3_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Nusinersen: first global approval. Drugs 77(4):473\u2013479. \nhttps:\/\/doi.org\/10.1007\/s40265-017-0711-7","journal-title":"Drugs"},{"issue":"10","key":"3_CR37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT et al (2016) Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86(10):890\u2013897. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000002445","journal-title":"Neurology"},{"issue":"10063","key":"3_CR38","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J et\u00a0al (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388(10063):3017\u20133026. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(16)31408-8","journal-title":"Lancet"},{"issue":"10","key":"3_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/01.NT.0000520478.96062.ee","volume":"17","author":"Thomas R. Collins","year":"2017","unstructured":"TR. Collins(2017) News from the AAN annual meeting: In Phase 3 results, infants on nusinersen survive longer, achieve motor milestones, vol 17. doi:\nhttps:\/\/doi.org\/10.1097\/01.NT.0000520478.96062.ee","journal-title":"Neurology Today"},{"issue":"3","key":"3_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.japh.2017.04.006","volume":"57","author":"DA Hussar","year":"2003","unstructured":"Hussar DA, Douglas DK (2003) Plecanatide, nusinersen, and obeticholic acid. J Am Pharm Assoc 57(3):416\u2013418. \nhttps:\/\/doi.org\/10.1016\/j.japh.2017.04.006","journal-title":"J Am Pharm Assoc"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-8651-4_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T16:13:37Z","timestamp":1543421617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-8651-4_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493986507","9781493986514"],"references-count":40,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-8651-4_3","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}